🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Mitral ValvE Repair Versus Watchful Waiting for Asymptomatic SEvere Degenerative Mitral Regurgitation

RecruitingNAAges 18 Years - 75 YearsAllCentre Hospitalier Universitaire, Amiens
NCT03389542 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Degenerative mitral regurgitation (MR) due to leaflet prolapse is frequent and can be surgically repaired in the vast majority of patients. Despite the efficacy of mitral valve repair, an ongoing international controversy exists regarding the need to perform early surgery in asymptomatic patients with severe MR and no sign of LV dysfunction in whom the probability of successful and durable repair is very high. In this group of patients, differing views of the risks of uncorrected severe MR exist: considered as benign by those supporting medical "watchful waiting" or associated with significant excess mortality/morbidity by those advocating early surgery. This controversy can only be resolved by a randomized controlled trial which is still lacking. The main objective is to demonstrate the superiority of early mitral valve repair in patients with asymptomatic severe MR due to leaflet prol

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Asymptomatic patients according history or an exercise test in those able to perform it if there is a doubt about the absence of symptoms * Severe (grade IV) degenerative MR due to leaflet prolapse assessed by echocardiography * LV ejection fraction by Simpson biplane method ≥60% and LV end-systolic diameter by TM echocardiography ≤40mm * Sinus rhythm on the inclusion ECG * Pulmonary artery pressure ≤50 mmHg by Doppler echocardiography. * High probability of mitral valve repair * EuroSCORE II ≤ 3% Exclusion Criteria: * Mitral stenosis or \> mild aortic valve disease (stenosis or regurgitation) * Congenital heart disease (except patent foramen ovale or atrial septal defect) * Patients with cardiac prostheses * Previous myocardial infarction * Previous cardiac surgery * Extra cardiac comorbidity with life expectancy \< 5 years * Recent history of psychiatric disease (including drug or alcohol abuse) * Therapy with an investigational intervention at the time of screening or plan to enrol patient in additional intervention study during participation in this trial
💊

What it tests

  • Surgery
  • Clinical interview and echocardiography
📍

Where

2 sites
CHU Amiens-Picardie
Amiens, France
Centre Cardiologique du Nord
Saint-Denis, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy